中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

白细胞介素28B的基因多态性与丙型肝炎病毒感染转归的关系

石晓东 姜晶 牛俊奇

石晓东, 姜晶, 牛俊奇. 白细胞介素28B的基因多态性与丙型肝炎病毒感染转归的关系[J]. 临床肝胆病杂志, 2011, 27(1): 28-31.
引用本文: 石晓东, 姜晶, 牛俊奇. 白细胞介素28B的基因多态性与丙型肝炎病毒感染转归的关系[J]. 临床肝胆病杂志, 2011, 27(1): 28-31.
Shi XiaoDong, Jiang Jing, Niu JunQi. Association of interleukin 28B(IL28B) polymorphisms with the outcomes of HCV infection[J]. J Clin Hepatol, 2011, 27(1): 28-31.
Citation: Shi XiaoDong, Jiang Jing, Niu JunQi. Association of interleukin 28B(IL28B) polymorphisms with the outcomes of HCV infection[J]. J Clin Hepatol, 2011, 27(1): 28-31.

白细胞介素28B的基因多态性与丙型肝炎病毒感染转归的关系

详细信息
  • 中图分类号: R512.63

Association of interleukin 28B(IL28B) polymorphisms with the outcomes of HCV infection

  • 摘要:

    丙型肝炎病毒(HCV)急性感染的患者,大约30%发生自发清除,已经进展为慢性丙型肝炎(CHC)的患者,经过抗病毒治疗,大约40%得到持久的HCV清除。近年来宿主基因变异在HCV感染治疗中的关键作用备受瞩目。今就近期的国内外报道,对白细胞介素(IL)28B的基因变异与HCV感染转归的关系进行综述。

     

  • [1]World Health Organization.Hepatitis C 2009,http://www.who.int/mediacentre/factsheets/fs164/cn.2002 Nov;36(5 Suppl 1):S35-46.
    [2]Seeff LB.Natural history of chronic hepatitis C[J].Hepatology,2002,36(5 Suppl 1):S35-46.
    [3]McHutchison JG,Everson GT,Gordon SC,et al.Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection[J].N Engl J Med,2009,360(18):1827-1838.
    [4]Shiffman ML,Lawitz EJ,Zaman A,et al.PEG-IFN-l:antiviral activity and safety profile in a 4-week phase 1b study in relapsed genotype 1 hepatitis C infection[J].Hepatology,2009,50(Suppl1):S237.
    [5]Kenny-Walsh E.Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin.Irish Hepatology Research Group[J].N Engl J Med,1999,340(16):1228-1233.
    [6]Muller R.The natural history of hepatitis C:clinical experiences[J].J Hepatol,1996,24(2 Suppl):52-54.
    [7]Sheppard P,Kindsvogel W,Xu W,et al.IL-28,IL-29 and their class II cytokine receptor IL-28R[J].Nat Immunol,2003,4(1):63-68.
    [8]Kotenko SV,Gallagher G,Baurin VV,et al.IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex[J].Nat Immunol,2003,4(1):69-77.
    [9]Sommereyns C,Paul S,Staeheli P,et al.IFN-lambda(IFNlambda)is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo[J].PLoS Pathog,2008,4(3):e1000017.
    [10]Ge D,Fellay J,Thompson AJ,et al.Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance[J].Nature,2009,461(7262):399-401.
    [11]Kau A,Vermehren J,Sarrazin C.Treatment predictors of a sustained virologic response in hepatitis B and C[J].J Hepatol,2008,49(4):634-651.
    [12]王东生,潘煜,牛俊奇,等.IL-28B基因变异与丙型肝炎的易感性及其自然清除的关系[J].临床肝胆病杂志,2010,26(5):496-499.
    [13]McCarthy JJ,Li JH,Thompson A,et al.Replicated Association between an IL28B Gene Variant and a Sustained Response to Pegylated Interferon and Ribavirin[J].Gastroenterology,2010,138(7):2307-2314.
    [14]Montes-Cano MA,García-Lozano JR,Abad-Molina C,et al.Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes[J].Hepatology,2010,52(1):33-37.
    [15]Tanaka Y,Nishida N,Sugiyama M,et al.Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C[J].Nat Genet,2009,41(10):1105-1109.
    [16]Suppiah V,Moldovan M,Ahlenstiel G,et al.IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy[J].Nat Genet,2009,41(10):1100-1104.
    [17]Rauch A,Kutalik Z,Descombes P,et al.Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure:a genome-wide association study[J].Gastroenterology,2010,138(4):1338-1345.
    [18]Thomas DL,Thio CL,Martin MP,et al.Genetic variation in IL28B and spontaneous clearance of hepatitis C virus[J].Nature,2009,461(7265):798-801.
    [19]Grebely J,Petoumenos K,Hellard M,et al.Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection[J].Hepatology,2010,52(4):1216-1224.
    [20]Rouch A,Rohrbach J,Bochuel PY,et al.The recent break throughs in the understanding of host genomics in hepatitis C[J].Eur J Clin Invest,2010,40(1):950-959.
    [21]Sarasin-Filipowicz M,Oakeley EJ,Duong FH,et al.Interferon signaling and treatment outcome in chronic hepatitis C[J].Proc Natl Acad Sci U S A,2008,105(19):7034-7039.
    [22]Urban TJ,Thompson AJ,Bradrick SS,et al.IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C[J].Hepatology,2010,20[Epub ahead of print].
  • 加载中
计量
  • 文章访问数:  8327
  • HTML全文浏览量:  18
  • PDF下载量:  2376
  • 被引次数: 0
出版历程
  • 出版日期:  2011-01-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回